search
Back to results

Use of Virtual Reality for Surgical Planning in Neuroblastoma (VRNB)

Primary Purpose

Neuroblastoma

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Immersive virtual reality imaging
Gold standard imaging
Sponsored by
Hospital Sant Joan de Deu
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuroblastoma focused on measuring virtual reality, neuroblastoma, surgery, planning, cancer, childhood

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pediatric patients (0-18 years) with neuroblastoma in L1, L2 or M stages (INGRSS) who have surgical indication for resection. Exclusion Criteria: Patients with relapsed neuroblastoma. Patients with neuroblastoma other than abdominal or pelvic location. Patients with previous surgery for the current diagnosis of neuroblastoma (excluding the biopsy that made the diagnosis). Patients who have undergone laparoscopic surgery. Patients operated on by a surgical team other than the one that usually treats oncology children at your center. Failure to obtain informed consent. Lack of complete medical records.

Sites / Locations

  • Hospital Sant Joan de DéuRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A

Group B

Arm Description

Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using gold standard imaging (TC and/or MRI) and immersive virtual reality HMD device.

Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using only gold standard imaging (TC and/or MRI)

Outcomes

Primary Outcome Measures

Surgical time
Reduction in surgical time when iVR is used

Secondary Outcome Measures

Full Information

First Posted
March 10, 2023
Last Updated
May 2, 2023
Sponsor
Hospital Sant Joan de Deu
search

1. Study Identification

Unique Protocol Identification Number
NCT05781919
Brief Title
Use of Virtual Reality for Surgical Planning in Neuroblastoma
Acronym
VRNB
Official Title
Use of Immersive Virtual Reality (iVR) for Surgical Planning in Neuroblastoma: A Randomized and Controlled Multicentric Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2023 (Anticipated)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
October 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Sant Joan de Deu

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Neuroblastoma is one of the most common extracranial solid tumors in children. It originates from cells of the neural crest, and can be located at the adrenal level, or in the sympathetic chains from the neck to the pelvis. Surgery still remains a mainstay part of the treatment and this is particularly challenging when IDRF are present. Adequate surgical planning, based on images such as CT Scans, MRI and/or nuclear medicine is crucial. This project seeks to compare; surgical time, GTR percentage and complications between standard surgical planning with biplanar 2D images vs the use of virtual reality as a planning tool, through the segmentation and post-processing of medical images and the visualization of 3D models with immersive virtual reality glasses (VR). The software that will be used for the segmentation and generation of 3D images will be Materialise Mimics® Innovation Suite and the images can be viewed using the Meta Quest 2® virtual reality glasses and the Materialise Mimics Viewer® software, which sends the processed images to be seen only by the treating surgeon, without patient data. The study design will be of the type of multicenter clinical trial, controlled and with simple randomization. All patients with a debut diagnosis of neuroblastoma in stage L1, L2 or M who have a surgical indication will be recruited. Surgical time, complications, amount of resection (GTR), surgeon's satisfaction as well as surgical anatomy comprehension will be compared. An invitation to participate will be sent to hospitals around the world.
Detailed Description
The study design will be a prospective, controlled, multicenter clinical trial with simple randomization, in patients with neuroblastoma in stages L1, L2 and M who require resective surgery. It will be a single-blind study (the patient will not know to which group he/she will be assigned) There will be two groups, which will be studied in parallel. Group A: Surgical planning with iRV. Group B: Surgical planning without iRV. The study group will be A, where the treating surgeon will use iVR, through the use of MetaQuest 2 ® glasses, as part of the surgical planning based on the 2D images of each patient (CT or MRI), and the control group will be B, where only the 2D images will be used for surgical planning. Randomization will be done through the database software REDCap®, which will assign each patient entering the study to one or another group, when the surgery is indicated. If the randomization corresponds to group A, the participating centers must send the 2D DICOM images to the research team of the coordinating center for segmentation and post-production into 3D images ready for viewing. This process will be carried out at the 3D4H Unit of the Hospital Sant Joan de Déu, with Materialise MIMICS® software, which generates a VR image file for viewing and control with the Meta Quest2® glasses. This file, encrypted and anonymized, will be sent to the corresponding participating center by e-mail, which can be opened only by the treating surgeon (who will have to create a username and password to access) and will not include the patient's identification data, only a unique code. The surgeon will use the aforementioned glasses to visualize and control the images. Once the VR images have been studied, the team will perform the surgery and record the intraoperative information on the data collection form. Each center has to obtain its own Meta Quest 2 or compatible goggles. In the event that the patient is randomized to Group B, the surgical team will do the surgical planning with 2D imaging, perform the surgery, and record the intraoperative information on the data collection form.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuroblastoma
Keywords
virtual reality, neuroblastoma, surgery, planning, cancer, childhood

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Experimental
Arm Description
Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using gold standard imaging (TC and/or MRI) and immersive virtual reality HMD device.
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using only gold standard imaging (TC and/or MRI)
Intervention Type
Other
Intervention Name(s)
Immersive virtual reality imaging
Intervention Description
Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
Intervention Type
Other
Intervention Name(s)
Gold standard imaging
Intervention Description
Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
Primary Outcome Measure Information:
Title
Surgical time
Description
Reduction in surgical time when iVR is used
Time Frame
From date of randomization until three months after surgery

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pediatric patients (0-18 years) with neuroblastoma in L1, L2 or M stages (INGRSS) who have surgical indication for resection. Exclusion Criteria: Patients with relapsed neuroblastoma. Patients with neuroblastoma other than abdominal or pelvic location. Patients with previous surgery for the current diagnosis of neuroblastoma (excluding the biopsy that made the diagnosis). Patients who have undergone laparoscopic surgery. Patients operated on by a surgical team other than the one that usually treats oncology children at your center. Failure to obtain informed consent. Lack of complete medical records.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Albert Pasten, MD
Phone
671589972
Ext
82455
Email
apastego44@alumnes.ub.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lucas Krauel, PhD
Organizational Affiliation
Hospital Sant Joan de Deu
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Sant Joan de Déu
City
Esplugues De Llobregat
State/Province
Barcelona
ZIP/Postal Code
08095
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rosa Balastegui
Phone
34932804000
Ext
71704
Email
rosamaria.balastegui@sjd.es

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Use of Virtual Reality for Surgical Planning in Neuroblastoma

We'll reach out to this number within 24 hrs